An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Health In Tech, Inc.
VERDICT
The label
Distribution
read at $1.13
Health In Tech, Inc. holds its Distribution at $1.13.
PHPhase · the trend structure carries the Distribution label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Distribution · caution
Quantitative state
The statistical read favours the buyers, held for 34 days
Price
$1.13
Valuation
N/A trailing · 7.88 forward price to earnings
Values screen
PASS· score 97.1
Beta
N/A
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OPPORTUNITY — it trades at roughly a 52% discount to our $1.71 fair value, weak competitive moat, 9.40% revenue growth.
Read at
$1.13
N/A P/E · 7.88 fwd
Our fair value
$1.71
52% discount
Analyst target (avg)
$4.00
+254% to current
Target low $4.00Analyst target rangeTarget high $4.10
▲ current $1.13 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$1.13
you are here
Conservative
$1.57
+39%
Analyst avg
$4.00
+254%
Our fair value
$1.71
+51%
Analyst high
$4.10
+263%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
9.40%
Profit margin
-2.37%
Debt to equity
0.56
Analyst consensus
None · 3 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 0.1% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 7.6% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 0.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Tech platform targets small business health cover
Picture a corner shop owner trying to offer staff decent cover without the usual insurer markups. Health In Tech steps in with reference pricing and captive programs that cut costs for firms too small for traditional brokers. The shares sit at 1.13 dollars against our 1.71 dollar fair value, a 52 percent margin of safety on a 7.9 times forward earnings multiple while revenue edges up 9 percent a year.
That valuation gap looks attractive next to the losses, yet the business still clears our ethical screen and shows real utility for overlooked employers. Three analysts see upside to a 4 dollar median target, and the platform model keeps fixed costs low once volumes rise.
Weak competitive protection and current negative margins of 2 percent plus a 5 percent negative return on equity leave plenty of room for execution slips or new entrants. Currency or reimbursement shifts could widen those gaps further before profits appear.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
HIT trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 85%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it strong buy, with a mean price target of $4. Entered 2026-07-18 · Markdown
JOURNAL
The dated journal · newest first, never edited
2026-07-18Markdown$0.99+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 85%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (3 analysts) rates it strong buy, with a mean price target of $4.
2026-07-03Markdown$0.99+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (97). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$0.99Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with near-perfect ethical score (97). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.